Impact of Skin Toxicities Associated with Targeted Cancer Therapies on Body Image: A Prospective Study

Overview

Journal Clin Drug Investig

Date 2016 Jan 13

PMID 26754775

Citations 3

Authors

Cecile Charles

Darius Razavi

Catherine Bungener

Christine Mateus

Emilie Lanoy

Michele Verschoore

Sarah Dauchy

Caroline Robert

Affiliations

Soon will be listed here.

Abstract

Background And Objective: Body-image issues associated with dermatological side effects induced by anticancer-targeted therapies have not been specifically explored until now despite growing literature about their impact on quality of life. Prospective and longitudinal investigations were needed. The aim of our study was to describe body-image changes occurring with cutaneous toxicities and their psychosocial impact on patients.

Patients And Methods: Thirty-three patients were evaluated four times during the first 3 months of targeted therapy in terms of body satisfaction, physical attitudes and depression with validated and ad hoc questionnaires. The NCI-CTCAE V4.0 was used to grade adverse dermatological events. Descriptive and inferential analyses were conducted with SPSS 14.0 software.

Results: Ninety-four per cent of the patients developed skin toxicities. Body satisfaction remained stable and slightly better than average over this period. About one-third of the patients reported body-image issues at baseline. Body satisfaction and depression levels at baseline appeared to be significantly associated with body-image issues after 3 months of therapy.

Conclusion: In the framework of regular dermatological monitoring, skin toxicities did not appear to be associated with body-image issues. Body satisfaction and depressive symptoms at the beginning of targeted therapy emerged as critical factors that practitioners should consider in order to prevent deterioration of body image that could impact on quality of life and compromise compliance.

Citing Articles

Body image and social appearance anxiety in patients with cancer undergoing radiotherapy: Across-sectional study.

Arikan F, Kartoz F, Karakus Z, Altinisik M, Ozer Z, Korcum Sahin A BMC Psychol. 2024; 12(1):363.

PMID: 38915070 PMC: 11194963. DOI: 10.1186/s40359-024-01856-w.

Dermatological Side Effects of Cancer Treatment: Psychosocial Implications-A Systematic Review of the Literature.

Almeida V, Pires D, Silva M, Teixeira M, Teixeira R, Louro A Healthcare (Basel). 2023; 11(19).

PMID: 37830658 PMC: 10572319. DOI: 10.3390/healthcare11192621.

EGFRI-associated health-related quality of life by severity of skin toxicity in metastatic colorectal cancer patients receiving epidermal growth factor receptor inhibitor target therapy.

Chiang T, Hsu H, Jane S, Chen S Support Care Cancer. 2020; 28(10):4771-4779.

PMID: 31974771 DOI: 10.1007/s00520-020-05321-3.

References

Charles C, Dauchy S . [Research on body image in oncology: a methodological synthesis]. Bull Cancer. 2011; 98(10):1209-20. DOI: 10.1684/bdc.2011.1453. View

Lacouture M, Basti S, Patel J, Benson 3rd A . The SERIES clinic: an interdisciplinary approach to the management of toxicities of EGFR inhibitors. J Support Oncol. 2006; 4(5):236-8. View

Koleck M, Bruchon-Schweitzer M, Cousson-Gelie F, Gilliard J, Quintard B . The body-image questionnaire: an extension. Percept Mot Skills. 2002; 94(1):189-96. DOI: 10.2466/pms.2002.94.1.189. View

Basra M, Finlay A . The family impact of skin diseases: the Greater Patient concept. Br J Dermatol. 2007; 156(5):929-37. DOI: 10.1111/j.1365-2133.2007.07794.x. View

Butts M, Jatoi A . Rash from newer cancer agents: why do we still not have effective therapy for palliation and/or prevention?. J Support Oncol. 2010; 8(4):162-3. PMC: 6015759. View

Hong J, Koo B, Koo J . The psychosocial and occupational impact of chronic skin disease. Dermatol Ther. 2008; 21(1):54-9. DOI: 10.1111/j.1529-8019.2008.00170.x. View

Stepanski E, Reyes C, Walker M, Satram-Hoang S, Leon L, Wojtowicz-Praga S . The association of rash severity with overall survival: findings from patients receiving erlotinib for pancreatic cancer in the community setting. Pancreas. 2012; 42(1):32-6. DOI: 10.1097/MPA.0b013e318254f19a. View

Wagner L, Berg S, Gandhi M, Hlubocky F, Webster K, Aneja M . The development of a Functional Assessment of Cancer Therapy (FACT) questionnaire to assess dermatologic symptoms associated with epidermal growth factor receptor inhibitors (FACT-EGFRI-18). Support Care Cancer. 2012; 21(4):1033-41. DOI: 10.1007/s00520-012-1623-4. View

Deslandres M, Sibaud V, Chevreau C, Delord J . [Cutaneous side effects associated with epidermal growth factor receptor and tyrosine kinase inhibitors]. Ann Dermatol Venereol. 2008; Spec No 1:16-24. DOI: 10.1016/S0151-9638(08)70093-0. View

10.

Pruzinsky T . Enhancing quality of life in medical populations: a vision for body image assessment and rehabilitation as standards of care. Body Image. 2007; 1(1):71-81. DOI: 10.1016/S1740-1445(03)00010-X. View

11.

Moreira H, Canavarro M . A longitudinal study about the body image and psychosocial adjustment of breast cancer patients during the course of the disease. Eur J Oncol Nurs. 2010; 14(4):263-70. DOI: 10.1016/j.ejon.2010.04.001. View

12.

Balagula Y, Rosen S, Lacouture M . The emergence of supportive oncodermatology: the study of dermatologic adverse events to cancer therapies. J Am Acad Dermatol. 2011; 65(3):624-635. DOI: 10.1016/j.jaad.2010.06.051. View

13.

Sibaud V, Dalenc F, Chevreau C, Roche H, Delord J, Mourey L . HFS-14, a specific quality of life scale developed for patients suffering from hand-foot syndrome. Oncologist. 2011; 16(10):1469-78. PMC: 3228077. DOI: 10.1634/theoncologist.2011-0033. View

14.

Sheppard L, Ely S . Breast cancer and sexuality. Breast J. 2008; 14(2):176-81. DOI: 10.1111/j.1524-4741.2007.00550.x. View

15.

Romito F, Giuliani F, Cormio C, Tulipani C, Mattioli V, Colucci G . Psychological effects of cetuximab-induced cutaneous rash in advanced colorectal cancer patients. Support Care Cancer. 2009; 18(3):329-34. DOI: 10.1007/s00520-009-0656-9. View

16.

Petrelli F, Borgonovo K, Cabiddu M, Lonati V, Barni S . Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials. Lung Cancer. 2012; 78(1):8-15. DOI: 10.1016/j.lungcan.2012.06.009. View

17.

Charles C, Sultan S, Bungener C, Mateus C, Lanoy E, Dauchy S . [Impact of cutaneous toxicities associated with targeted therapies on quality of life. Results of a longitudinal exploratory study]. Bull Cancer. 2013; 100(3):213-22. DOI: 10.1684/bdc.2013.1709. View

18.

Petrelli F, Borgonovo K, Barni S . The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trials. Target Oncol. 2013; 8(3):173-181. DOI: 10.1007/s11523-013-0257-x. View

19.

Andreis F, Rizzi A, Mosconi P, Braun C, Rota L, Meriggi F . Quality of life in colon cancer patients with skin side effects: preliminary results from a monocentric cross sectional study. Health Qual Life Outcomes. 2010; 8:40. PMC: 2861022. DOI: 10.1186/1477-7525-8-40. View

20.

Mateus C, Robert C . [New drugs in oncology and skin toxicity]. Rev Med Interne. 2009; 30(5):401-10. DOI: 10.1016/j.revmed.2009.02.001. View